CA3116347C - Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1 - Google Patents

Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1

Info

Publication number
CA3116347C
CA3116347C CA3116347A CA3116347A CA3116347C CA 3116347 C CA3116347 C CA 3116347C CA 3116347 A CA3116347 A CA 3116347A CA 3116347 A CA3116347 A CA 3116347A CA 3116347 C CA3116347 C CA 3116347C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
inhibitors
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3116347A
Other languages
English (en)
Other versions
CA3116347A1 (fr
Inventor
Gayatri Balan
Mark J. Bartlett
Jayaraman Chandrasekhar
Julian A. Codelli
John H. Conway
Jennifer L. Cosman
Rao V. Kalla
Musong Kim
Seung H. Lee
Jennifer R. LO
Jennifer A. Loyer-Drew
Scott A. Mitchell
Thao D. Perry
Gary B. Phillips
Patrick J. Salvo
Joshua J. Van Veldhuizen
Suet C. Yeung
Jeff Zablocki
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Priority claimed from PCT/US2019/058813 external-priority patent/WO2020092528A1/fr
Publication of CA3116347A1 publication Critical patent/CA3116347A1/fr
Application granted granted Critical
Publication of CA3116347C publication Critical patent/CA3116347C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Il est essentiellement décrit certains composés de 6-azabenzimidazole de la Formule I, des sels pharmaceutiquement acceptables de ceux-ci, des compositions pharmaceutiques comprenant les composés décrits ainsi que des méthodes de production et d'utilisation des compositions pharmaceutiques et des compositions décrites. Les compositions et composés décrits peuvent servir aux fins de traitement ou de prévention de maladies, de troubles et d'infections pouvant être modifiés par des inhibiteurs de la kinase des progéniteurs hématopoïétiques 1 (HPK1), comme le virus de l'hépatite B, le virus de l'immunodéficience humaine, le cancer et/ou une maladie hyper-prolifératives.
CA3116347A 2018-10-31 2019-10-30 Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1 Active CA3116347C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862753355P 2018-10-31 2018-10-31
US62/753,355 2018-10-31
PCT/US2019/058813 WO2020092528A1 (fr) 2018-10-31 2019-10-30 Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1

Publications (2)

Publication Number Publication Date
CA3116347A1 CA3116347A1 (fr) 2020-05-07
CA3116347C true CA3116347C (fr) 2025-10-28

Family

ID=

Similar Documents

Publication Publication Date Title
US11925631B2 (en) Substituted 6-azabenzimidazole compounds
US12258346B2 (en) Substituted 6-azabenzimidazole compounds
WO2020072656A1 (fr) Dérivés d'imidozopyrimidine
CA3116347C (fr) Composes 6-azabenzimidazole substitues ayant une activite inhibitrice de hpk1
HK40111208A (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
HK40111208B (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
HK40061574A (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
HK40061574B (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EA048040B1 (ru) Замещенные соединения 6-азабензимидазола
EA045798B1 (ru) Замещенные соединения 6-азабензимидазола
HK40051993B (zh) 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物